Functional characterization of an eosinophil-specific galectin, ovine galectin-14
Across mammalian species, human galectin-10 and ovine galectin-14 are unique in their expression in eosinophils and their release into lung and gastrointestinal tissues following allergen or parasite challenge. Recombinant galectin-14 is active in carbohydrate binding assays and has been used in this study to unravel the function of this major eosinophil constituent. In vitro cultures revealed that galectin-14 is spontaneously released by eosinophils isolated from allergen-stimulated mammary gland lavage, but not by resting peripheral blood eosinophils. Galectin-14 secretion from peripheral blood eosinophils can be induced by the same stimuli that induce eosinophil degranulation. Flow cytometric analysis showed that recombinant galectin-14 can bind in vitro to eosinophils, neutrophils and activated lymphocytes. Glycan array screening indicated that galectin-14 recognizes terminal N-acetyllactosamine residues which can be modified with α1-2-fucosylation and, uniquely for a galectin, prefers α2- over α2-sialylation. Galectin-14 showed the greatest affinity for lacto-N-neotetraose, an immunomodulatory oligosaccharide expressed by helminths. Galectin-14 binds specifically to laminin in vitro, and to mucus and mucus producing cells on lung and intestinal tissue sections. In vivo, galectin-14 is abundantly present in mucus scrapings collected from either lungs or gastrointestinal tract following allergen or parasite challenge, respectively. These results suggest that in vivo secretion of eosinophil galectins may be specifically induced at epithelial surfaces after recruitment of eosinophils by allergic stimuli, and that eosinophil galectins may be involved in promoting adhesion and changing mucus properties during parasite infection and allergies.
KeywordsGalectin Eosinophil Mucus Glycan array Allergy Helminth
We wish to acknowledge the Consortium for Functional Glycomics Grant number GM62116 for performing the glycan array screening. This work was supported by grants from the Australian Research Council.
- 2.Rabinovich, G.A., Liu, F.T., Hirashima, M., Anderson, A.: An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand. J. Immunol. 66, 143–158 (2007). doi: 10.1111/j.1365-3083.2007.01986.x PubMedCrossRefGoogle Scholar
- 7.Kaltner, H., Solis, D., Kopitz, J., Lensch, M., Lohr, M., Manning, J.C., et al.: Prototype chicken galectins revisited: characterization of a third protein with distinctive hydrodynamic behaviour and expression pattern in organs of adult animals. Biochem. J. 409, 591–599 (2008). doi: 10.1042/BJ20070419 PubMedCrossRefGoogle Scholar
- 8.Dunphy, J.L., Barcham, G.J., Bischof, R.J., Young, A.R., Nash, A., Meeusen, E.N.: Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge. J. Biol. Chem. 277, 14916–14924 (2002). doi: 10.1074/jbc.M200214200 PubMedCrossRefGoogle Scholar
- 9.Ackerman, S.J., Corrette, S.E., Rosenberg, H.F., Bennett, J.C., Mastrianni, D.M., Nicholson-Weller, A., et al.: Molecular cloning and characterization of human eosinophil Charcot–Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily. J. Immunol. 150, 456–468 (1993)PubMedGoogle Scholar
- 10.Ackerman, S.J., Liu, L., Kwatia, M.A., Savage, M.P., Leonidas, D.D., Swaminathan, G.J., et al.: Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J. Biol. Chem. 277, 14859–14868 (2002). doi: 10.1074/jbc.M200221200 PubMedCrossRefGoogle Scholar
- 28.Terrazas, L.I., Walsh, K.L., Piskorska, D., McGuire, E., Harn Jr., D.A.: The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections. J. Immunol. 167, 5294–5303 (2001)PubMedGoogle Scholar